AUA 2023热点速递：前列腺癌临床诊疗进展

倪栋; 章小平

doi:10.13201/j.issn.1001-1420.2023.06.012

AUA 2023热点速递：前列腺癌临床诊疗进展

倪栋¹,
章小平^1, ,

- 华中科技大学同济医学院附属协和医院泌尿外科(武汉，430022)

详细信息

通讯作者: 章小平，E-mail：xzhang@hust.edu.cn

中图分类号: R737.25

收稿日期: 2023-05-10

刊出日期: 2023-06-06

Highlights from AUA 2023: the clinical advances in the diagnosis and treatment of prostate cancer

NI Dong¹,
ZHANG Xiaoping^1, ,

- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: ZHANG Xiaoping, E-mail: xzhang@hust.edu.cn

Received Date: 10 May 2023

Publish Date: 06 June 2023

摘要

摘要: 2023年4月28日—5月1日，美国泌尿外科协会(AUA)年会在美国芝加哥召开，展示了泌尿外科领域的最新进展。本文就会议聚焦的前列腺癌诊断、手术、综合性治疗以及指南更新等方面做简要介绍。
- 前列腺癌 /
- 早期检测 /
- PSMA-PET /
- 临床试验
Abstract: The American Urological Association (AUA) Annual Meeting was held in Chicago, USA, from April 28th to May 1st, 2023, showcasing the recent advancements in the field of urology. This article provides a brief overview of the conference's focus on prostate cancer diagnosis, surgery, systemic treatment and guideline updates.
- prostate cancer /
- early detection /
- PSMA-PET /
- clinical trial

HTML全文

参考文献(10)

[1]	Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part Ⅰ: Prostate Cancer Screening[J]. J Urol, 2023: 101097JU0000000000003491. doi: 10.1097/JU.0000000000003491
[2]	Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part Ⅱ: Considerations for a Prostate Biopsy[J]. J Urol, 2023: 101097JU0000000000003492. doi: 10.1097/JU.0000000000003492
[3]	Scuderi S. The Prognostic Impact of Preoperative PSMA-PET on Early Oncological Outcomes in Prostate Cancer Patients Treated With Radical Prostatectomy: Results of a Multi-center Analysis[R]. Chicago: American Urological Association(AUA)Annual Meeting 2023 Podium Session.
[4]	Touijer KA. Role and Extent of Pelvic Lymph Node Dissection in PSMA Era[R]. Chicago: American Urological Association(AUA)Annual Meeting 2023 Arab Association of Urology Forum session.
[5]	Masterson TA, Bianco FJ Jr, Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer[J]. J Urol, 2006, 175(4): 1320-1324;discussion 1324-1325. doi: 10.1016/S0022-5347(05)00685-3
[6]	Touijer KA, Sjoberg DD, Benfante N, et al. Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial[J]. Eur Urol Oncol, 2021, 4(4): 532-539 http://pubmed.ncbi.nlm.nih.gov/33865797/
[7]	Luiting HB, van Leeuwen PJ, Busstra MB, et al. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature[J]. BJU Int, 2020, 125(2): 206-214.
[8]	Robesti D. The Prognostic Role of 68ga-PSMA PET/CT and the Impact of Metastasis-Directed Therapy on Cancer Progression in Men With Biochemical Recurrence From Prostate Cancer: Results From a Large, Single Institution Series[R]. Chicago: American Urological Association(AUA)Annual Meeting 2023 Moderated Poster Session.
[9]	Lowentritt B. PSA Response and Time-to-Castration Resistance among Patients with Metastatic Castration Sensitive Prostate Cancer Initiated on Apalutamide, Enzalutamide, or Abiraterone[R]. Chicago: American Urological Association(AUA)Annual Meeting 2023 Moderated Poster Session.
[10]	Eggener S. Updated Progression-Free Survival from PRESTO: a Phase 3 Randomized Study of Androgen Annihilation for High-Risk Biochemically Relapsed Prostate Cancer(AFT-19)[R]. Chicago: American Urological Association(AUA)Annual Meeting 2023 Podium Session.